Full-Time

Senior Director / Director

Program Management

Confirmed live in the last 24 hours

Vor Bio

Vor Bio

51-200 employees

Develops targeted therapies for blood cancers

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

This position is located onsite in our Cambridge, MA office.

Category
Biology Lab & Research
Biology & Biotech

You match the following Vor Bio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • B.S. or M.S. in the life sciences. Advanced degree preferred.
  • 10-15+ years of relevant biopharmaceutical industry experience, including mid to late-stage clinical development and execution of registrational and/or Phase 3 clinical trials.
  • 7-10 years of program management experience in a fast-paced, innovative biotech/pharma company.
  • Expert knowledge of business and project planning software, including experience integrating new software platforms into organizations.
Responsibilities
  • Collaborate with the SVP of Portfolio Strategy and Program Management and Program Strategy Team (PST) members to define and execute cross-functional strategies aligned with corporate goals.
  • Work with the Program Strategy Team, clinical development functions, and cross-functional sub-teams to translate program strategies into efficient, executable operational plans aligned with timelines and budgets.
  • Develop and own program timelines, cross-functional risk mitigation plans, budgets, and Target Product Profiles (TPPs). Drive cross-functional alignment and manage operational priorities.
  • Partner with the clinical development team, including the CMO, to support ongoing and future clinical studies, ensuring integration and connectivity to overall program planning.
  • Establish and own flexible program timelines, including milestones, interdependencies, reporting tools, communication strategies, and contingency planning. Ensure budget support in collaboration with SVP, PSPM, and finance.
  • Plan, schedule, and drive strategic program team meetings, fostering a culture of ownership, accountability, and continuous improvement. Develop high-performing teams. Foster a collaborative team culture where everyone feels highly engaged and confident in sharing their ideas and perspectives.
  • Effectively communicate with internal stakeholders on the status, goals, risks, and mitigation plans of various programs.
  • Build healthy and collaborative relationships with functional experts across the organization. Provide cross-functional program management for development and business functions as needed.
  • Contribute to organization-wide strategic planning activities, including support for organizational and change management.
  • Support informed decision-making at Vor Bio.
  • Guide and mentor talent at Vor Bio.
  • Help evaluate and evolve the Portfolio Strategy and Program Management function to set a solid foundation for the design, development, and delivery of transformative therapies to patients.
Desired Qualifications
  • Experience with cell and gene therapy and oncology drug development preferred, but not required.

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from its competitors is its commitment to extensive research and development of novel therapies, supported by a team with significant experience in the biopharmaceutical field. The company generates revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. Ultimately, Vor Biopharma aims to transform the treatment landscape for blood cancers by providing safer and more effective treatment options.

Company Size

51-200

Company Stage

IPO

Total Funding

$147.9M

Headquarters

Cambridge, Massachusetts

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $55.6M funding supports clinical trials and extends cash runway to 2025.
  • FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.
  • Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

What critics are saying

  • Significant YTD price decline of -62.76% may affect investor confidence.
  • Key clinical trial data updates are not expected until 2025, causing uncertainty.
  • Increased competition from companies like Editas Medicine poses potential conflicts.

What makes Vor Bio unique

  • Vor Bio focuses on protecting healthy cells while targeting cancerous ones.
  • The company specializes in innovative treatments for blood cancers like AML.
  • Vor Bio's approach aligns with the rise of personalized medicine.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

10%
Street Insider
Jan 8th, 2025
Vor Biopharma (VOR) Appoints Erez Kalir to its Board

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors.

Vor Bio
Dec 30th, 2024
Vor Bio Announces $55.6 Million Private Placement | Vor Bio

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101

Benzinga
Dec 27th, 2024
Vor Bio Secures $55.6M in Funding

Vor Biopharma announced a $55.6 million private placement led by Reid Hoffman, with participation from RA Capital Management. The deal involves issuing 55,871,260 shares and warrants for 69,839,075 shares at $0.99425 each. Warrants have a $0.838 exercise price, potentially adding $58.5 million. The funds will support clinical trials, with data updates expected in 2025. The PIPE is set to close on December 30, 2024, pending customary conditions.

GlobeNewswire
May 7th, 2024
Dbv Technologies Reports First Quarter 2024 Financial Results And Business Update

Montrouge, France, May 7, 2024DBV Technologies Reports First Quarter 2024 Financial Results and Business UpdateVITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 millionDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024.Recent Business DevelopmentsClinical and Regulatory UpdateEnrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by Q3 2024. VITESSE is a trial evaluating efficacy and safety in approximately 600 subjects (randomized 2:1) with 86 participating sites in US, Canada, Europe, UK and Australia.“We are pleased with VITESSE enrollment rates and thrilled that our sites in Europe and the UK are actively enrolling subjects and have increased the momentum for VITESSE,” said Pharis Mohideen, M.D. Chief Medical Officer at DBV Technologies. “This comes on the heels of the February AAAAI meeting where there was tremendous interest in Viaskin Peanut and standing room only, record breaking attendance at our product theatre “Importance of Early Intervention for Peanut Allergy.”The Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 through 3-year-olds to the FDA on November 9, 2023. The Company and the FDA are engaged in ongoing dialogue related to the program.Appointment of Robert Pietrusko, Chief Regulatory OfficerDBV has strengthened its regulatory expertise by appointing Robert Pietrusko, PharmD, to the position of Chief Regulatory Officer

Street Insider
May 3rd, 2024
Vor Biopharma (VOR) Appoints Fouad Namouni to its Board

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors.